Objectives-Serious upper gastrointestinal events are an important threat to patients with arthritis who are treated with non-steroidal anti-inflammatory
patients, in four of whom a perforated ulcer was found. The deaths of five patients (5%) were related to a serious upper gastrointestinal event, which corresponds to the death rate in other studies.4 Table 2 gives the odds ratio for selected variables for serious upper gastrointestinal events based on the data from the full study population. Significant differences were found for age (over 70 years); the presence of the ACR criteria for arthritis in more than three joints, symmetrical arthritis, and rheumatoid factor; the presence of more than four ACR criteria; the presence of bony erosions; the presence of amyloidosis; the presence of IlOdds ratio for the presence of extra-articular manifestations other than nodules or cryoglobulinaemia. Extra-articular and systemic manifestations of RA were more often present among cases than among controls (tables 4 and 5). Vasculitis was reported from 11 biopsy samples in an equal number of cases. This included eight skin biopsy samples. Other specimens were taken from the rectum, jejunum, and kidney. Skin biopsy samples showed vasculitis in two control patients.
The odds ratio for a serious upper gastrointestinal event, as calculated with a conditional logistic regression analysis, was higher when multiple extra-articular disease features were present (table 4). In the presence of extra-articular disease manifestations other than rheumatoid nodules and cryoglobulinaemia the odds ratio was 11 2, independent of a history of peptic disease and corticosteroid use. In matched patients fulfilling the ACR criteria for RA, the adjusted odds ratio was 9 3. Discussion Non-steroidal anti-inflammatory drug gastropathy is usually asymptomatic and self limiting (gastric adaptation has been suggested), and there is no conclusive evidence that the lesions bleed or progress to gastric ulceration.' 5 6 12 Serious gastrointestinal events are much more important from a clinical point of view. Peptic ulceration, which is sometimes masked by the analgesic effect of NSAIDs, can lead to haemorrhage or perforation, which can result in sudden death. The incidence rate found in this retrospective study-four serious upper gastrointestinal events in 1000 patients with RA in a year-is comparable with the rates given in previous studies. 1 3 Our results confirm that several previously reported factors are associated with a higher risk for a serious upper It has often been suggested that RA is associated with an increased risk for peptic ulceration.' 3 6 13 This was left unconfirmed in a study by Malone et al.9 The present study population is not suitable for investigating the risk associated with RA itself, as a clinical diagnosis of RA was the primary inclusion criterion. The risk for a serious upper gastrointestinal event among patients with possible RA was half that among patients who fulfilled the ACR criteria (table 2), however.
The purpose of this study was to investigate the influence of specific manifestations of RA on serious upper gastrointestinal events. The context for this is the widely reported, but controversial, association between peptic ulceration and the concurrent use of corticosteroids and NSAIDs. 8 14-16 This combination of drugs is probably used more often in the treatment of RA than in that of any other disease. It is not known whether the risk associated with steroids arises from drug toxicity alone or from toxicity in combination with the severity of the underlying disease. The usual reason for starting corticosteroid treatment is unresponsiveness to NSAIDs and DMARDs, or the appearance of extra-articular manifestations. The increased frequency of serious upper gastrointestinal events could, therefore, be a direct consequence of widespread inflammatory activity. It is also possible that peptic ulceration is itself an extraarticular manifestation of RA.
In the initial evaluation of our patient data we observed associations of serious upper gastrointestinal events with factors related to severity of joint disease, with the presence of extra-articular manifestations, and also with treatment with certain DMARDs or corticosteroids (table 2) . These associations were also present when the data were stratified for these variables, though not statistically significant for extra-articular manifestations (defined as vasculitis, serositis, Sjogren's syndrome, and rheumatoid nodules) ( We observed the highest risk in a group of 37 cases in whom extra-articular manifestations other than nodules or cryoglobulinaemia occurred. We think it improbable that this risk is attributable to the use of corticosteroids, which had been prescribed because of the greater severity of the disease. Corticosteroids were used by only 12 of these 37 patients (32%) at the times of the serious upper gastrointestinal events and by two of five matched control patients (40/O). It cannot be excluded, however, that the case patients were using higher doses of NSAIDs. Data on the doses used at the times of ulceration could, unfortunately, not be assessed reliably from the patients' notes. Smoking rate, another supposed risk factor for gastrointestinal ulcers, also could not reliably be obtained from the charts.
The integrity of the gastrointestinal mucosa depends on the balance between defensive and offensive mechanisms. The results of this study suggest that the severity of RA is an independent factor in ulcer formation. Two hypotheses can be considered to explain this. Firstly, increased levels of proinflammatory substances-for example, cytokines or toxic products-may accelerate ulcer formation.17 18 Secondly, the impairment of mucosal blood flow may hinder defensive mechanisms.' '9 Indomethacin and aspirin rapidly induce microvascular damage to venules and reduce mucosal blood flow.'9 20 Leucocyte adhesion is an important additional factor in the subsequent process leading to mucosal damage.2' 22 Thus conditions that alter local blood flow may be risk factors for gastric mucosal damage. Extra-articular manifestations of RA are commonly accompanied by inflammation of the vascular wall.
Our data suggest that severe RA, in particular the presence of extra-articular or systemic manifestations, is a significant risk factor for serious upper gastrointestinal events and that the risk is independent of the use of corticosteroids. The implication is that patients with RA with extra-articular disease manifestations need careful monitoring and, perhaps, prophylaxis. The effectiveness of prophylaxis in this high risk group has yet to be established.
